uBriGene to Showcase Innovations at ASH 2024

mRNA-LNP Mediated CAR-T Manufacturing from uBriGene Set to Shine at ASH 2024

Discover uBriGene's advancements at the Advanced Therapies 2024

Discover uBriGene’s Innovations at The Advanced Therapies Congress 2024!

Completion of series C round funding

uBriGene Biosciences completes several hundred million yuan Series C round funding

20 million USD Series C+ round closed

uBriGene Biosciences Inc. closes 150 million CNY (20 million USD) Series C+ round

Targets North American growth with major acquisition

Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition

Mustang Bio transaction completion

uBriGene (Boston) Biosciences completed the transaction with Mustang Bio, Inc. (Nasdaq: MBIO)

uBriGene exhibits at ASGCT2024

uBriGene will exhibit at ASGCT2024 this May 7 – 11 in Baltimore

uBrigene's showcase at ISCT2024

uBriGene's showcase at ISCT2024 Vancouver May 29 - Jun 1

Meet uBriGene at BIO2024

Join uBriGene Biosciences to Discover the Future of Biotech at BIO San Diego Jun 03 - 06!

Pioneering Gene Therapy: uBriGene as Your Strategic Partner

uBriGene Biosciences Congratulates Strategic Partner InnoVec Biotherapeutics on FDA Clearance of IND for IVB103, An AAV-based Gene Therapy